Precision BioSciences, Inc.

DB:PBS0 Stock Report

Market Cap: €35.6m

Precision BioSciences Valuation

Is PBS0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PBS0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
€35.25
Fair Value
87.5% undervalued intrinsic discount
5
Number of Analysts

Below Fair Value: PBS0 (€4.4) is trading below our estimate of fair value (€35.25)

Significantly Below Fair Value: PBS0 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PBS0?

Key metric: As PBS0 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for PBS0. This is calculated by dividing PBS0's market cap by their current earnings.
What is PBS0's PE Ratio?
PE Ratio3x
EarningsUS$11.48m
Market CapUS$36.74m

Price to Earnings Ratio vs Peers

How does PBS0's PE Ratio compare to its peers?

The above table shows the PE ratio for PBS0 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average11.6x
2INV 2invest
13.4xn/a€67.3m
FYB Formycon
16.8x22.6%€1.1b
BIO3 Biotest
15.6x29.3%€1.3b
ECX Epigenomics
0.5xn/a€1.4m
PBS0 Precision BioSciences
3x-31.6%€36.7m

Price-To-Earnings vs Peers: PBS0 is good value based on its Price-To-Earnings Ratio (3x) compared to the peer average (11.6x).

Price to Earnings Ratio vs Industry

How does PBS0's PE Ratio compare vs other companies in the European Biotechs Industry?

6 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.28.8x34.6%
PBS0 Precision BioSciences
 3x-31.6%US$36.74m
PBS0 3.0xIndustry Avg. 28.8xNo. of Companies5PE020406080100+
6 CompaniesEstimated GrowthMarket Cap
Industry Avg.28.8x34.6%
PBS0 Precision BioSciences
 3x-31.6%US$36.74m
No more companies

Price-To-Earnings vs Industry: PBS0 is good value based on its Price-To-Earnings Ratio (3x) compared to the European Biotechs industry average (28.9x).

Price to Earnings Ratio vs Fair Ratio

What is PBS0's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PBS0 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio3x
Fair PE Ratio5.1x

Price-To-Earnings vs Fair Ratio: PBS0 is good value based on its Price-To-Earnings Ratio (3x) compared to the estimated Fair Price-To-Earnings Ratio (5.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PBS0 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€4.40
€32.20
+631.9%
42.0%€57.50€18.21n/a5
Jan ’26€4.40
€32.20
+631.9%
42.0%€57.50€18.21n/a5
Dec ’25€6.70
€30.89
+361.1%
42.0%€55.16€17.47n/a5
Nov ’25€8.00
€33.12
+313.9%
42.1%€55.58€17.60n/a4
Oct ’25€7.75
€30.33
+291.4%
42.0%€54.16€17.15n/a5
Sep ’25€9.65
€30.59
+217.0%
39.3%€55.62€17.61n/a6
Aug ’25€9.20
€30.59
+232.5%
39.3%€55.62€17.61n/a6
Jul ’25€9.00
€30.59
+239.9%
39.3%€55.62€17.61n/a6
Jun ’25€10.80
€30.59
+183.3%
39.3%€55.62€17.61n/a6
May ’25€9.05
€30.91
+241.6%
39.3%€56.21€17.80n/a6
Apr ’25€12.20
€34.68
+184.3%
36.3%€55.86€23.28n/a4
Mar ’25€11.66
€74.57
+539.5%
17.7%€83.89€55.93n/a3
Feb ’25€9.30
€73.59
+691.3%
17.7%€82.79€55.19n/a3
Jan ’25€9.84
€74.70
+659.2%
17.7%€84.04€56.03€4.403
Dec ’24€9.60
€74.70
+678.2%
17.7%€84.04€56.03€6.703
Nov ’24€7.98
€73.30
+818.5%
38.1%€112.76€39.47€8.004
Oct ’24€9.12
€73.30
+703.7%
38.1%€112.76€39.47€7.754
Sep ’24€12.60
€75.42
+498.5%
52.0%€137.96€27.59€9.656
Aug ’24€15.45
€83.45
+440.2%
54.1%€136.07€27.21€9.206
Jul ’24€14.34
€181.50
+1,165.7%
74.8%€462.83€27.23€9.006
Jun ’24€20.70
€181.50
+776.8%
74.8%€462.83€27.23€10.806
May ’24€22.20
€181.50
+717.6%
74.8%€462.83€27.23€9.056
Apr ’24€20.08
€167.76
+735.6%
81.6%€475.32€27.96€12.207
Mar ’24€31.56
€185.37
+487.4%
73.3%€469.35€27.61€11.667
Feb ’24€32.30
€185.37
+474.0%
73.3%€469.35€27.61€9.307
Jan ’24€27.99
€194.99
+596.7%
69.6%€500.36€29.43€9.848
Analyst Price Target
Consensus Narrative from 5 Analysts
€32.85
Fair Value
86.6% undervalued intrinsic discount
5
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 14:32
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Precision BioSciences, Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Konstantinos BiliourisBMO Capital Markets Equity Research
Debjit ChattopadhyayGuggenheim Securities, LLC
Debjit ChattopadhyayH.C. Wainwright & Co.